echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > NEJM: Evaluation of the efficacy of the new crown pneumonia vaccine in the United States after mass vaccination

    NEJM: Evaluation of the efficacy of the new crown pneumonia vaccine in the United States after mass vaccination

    • Last Update: 2021-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The new crown pneumonia vaccine has played a key role in suppressing the spread of the epidemic.
    Recently, researchers announced that after a large-scale vaccination, the three vaccines, BNT162b2, mRNA-1273 and Ad26.
    COV2.
    S, will reduce the hospitalization and hospitalization of severely ill high-risk patients with new coronary pneumonia.
    The effect of ICU risk and emergency hospital admission risk for new coronary pneumonia
    .

    New coronary pneumonia researchers recently announced the effects of the three vaccines, BNT162b2, mRNA-1273 and Ad26.
    COV2.
    S, on reducing the hospitalization and ICU risk of new coronary pneumonia in patients with severe high-risk patients and the risk of emergency hospital admission for new coronary pneumonia after a large-scale vaccination
    .


    Recently, researchers announced the effects of the three vaccines, BNT162b2, mRNA-1273 and Ad26.


    Patients over the age of 50 who underwent nucleic acid testing for suspected new coronary pneumonia participated in the study, including 41552 inpatient cases in 187 hospitals and 21522 cases in 221 emergency centers from January 1 to June 22, 2021 Situation
    .


    According to the electronic health record and immunization registration status, the patient's vaccination status is obtained.


    immunity

    After completing the mRNA vaccination (14 days after the second vaccination), the vaccine's effectiveness in preventing SARS-CoV-2 infection leading to hospitalization was 89% (95% CI: 87-91), and its effectiveness in preventing ICU admission was 90%, the effectiveness of emergency department visits related to the prevention of new coronary pneumonia is 91%
    .


    The protective effects of BNT162b2 and mRNA-1273 vaccines range from 81% to 95% in people over 85 years of age, chronic diseases, and black or Hispanic people


    After completing the mRNA vaccination (14 days after the second vaccination), the vaccine's effectiveness in preventing SARS-CoV-2 infection leading to hospitalization was 89% (95% CI: 87-91), and its effectiveness in preventing ICU admission was 90%, the effectiveness of emergency department visits related to the prevention of new coronary pneumonia is 91%


    In the United States, after large-scale vaccination of the three vaccines BNT162b2, mRNA-1273 and Ad26.


    In the United States, after mass vaccination of the three vaccines BNT162b2, mRNA-1273 and Ad26.


    Original source:

    Mark G.


    Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.